



COMPANY DESCRIPTION

FORMYCON is a leading and independent developer of high-quality biosimilars. The team of FORMYCON has extensive experience in complex biological molecules and is able to meet the high standards of the world's most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia, through its particular expertise. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases. FORMYCON currently has four biosimilars in development. Two of them have already been licensed to Bioeq IP AG and Santo Holding GmbH while a third will be further developed in a joint venture with Aristo Pharma GmbH. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets. Analysts expect worldwide biosimilar-revenue to grow up to USD 15 billion by the year 2020. This number could even double by the year 2025. Because of their size and structural complexity, and their production using living cell systems, biosimilars require very significant time, effort and expertise, both in their development and in their subsequent production.

| PIPELINE | Reference Product Active Ingredient Disease Area | Indications | Partner | Preclinical Phase | Clinical Phase I | Clinical Phase III |
|-------------------|--|--------------------------------------|--------------------------|--------------------------|---------------------|-----------------------|
| FYB 201 | Lucentis® Ranibizumab Ophthalmology | wAMD, DME, RVO, mCNV, DR* | Bioeq IP AG | ✓ | ✓ | ✓ |
| FYB 202 | Stelara® Ustekinumab Immunology | Pso, PsA, CD, UC | Aristo Pharma GmbH | Phase I Start Oct. 19 | | |
| FYB 203 | Eylea® Aflibercept Ophthalmology | wAMD, DME, RVO, DR*, mCNV** | Santo Holding GmbH | Phase III Start Mid 2020 | | |
| FYB 205 | 🔒 | 🔒 | | | | |

* FDA approved only ** EMA approved only

STRATEGY & GOALS

FORMYCON is specifically concentrating on the "third wave" of biosimilars, namely follow-on products for blockbuster biopharmaceuticals with patent expiries beginning in the year 2020. Because FORMYCON has focused its efforts on this generation of biosimilars at a timely stage, the company has been able to carve out for itself a unique and leading position in this market space. It's the strategic goal to further strengthen that status and, as a leading independent developer of biosimilars, to assume a key role in this global market. FORMYCON strives to cover the entire value creation chain, from technical-pharmaceutical development to the clinical trials as well as the preparation of dossiers for marketing approval. Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments. Through its biosimilars, FORMYCON will help not only patients around the world but also contributes to ease the financial strains on the world's healthcare systems.

FACTS

| | |
|--------------------------|---|
| Founded | 2007 |
| Headquarters | Planegg / Munich |
| Employees | > 100 |
| Management | Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combé (CFO) Dr. Stefan Glombitza (COO) |
| Supervisory Board | Dr. Olaf Stiller (Chairman) Hermann Vogt (Deputy Chairman) Peter Wendeln (Member Supervisory Board) |

KEY FINANCIALS (in € million)

| | 2016 | 2017 | 2018 | 2019e* |
|--------------------------------|------|------|------|--------|
| Revenue | 19.5 | 29.4 | 43.0 | 38.0 |
| Operating Income (EBIT) | -4.1 | -1.5 | 7.1 | -3.5 |
| Net Income | -4.1 | -1.6 | 7.1 | -3.7 |
| Equity Ratio (in %) | 82.9 | 82.9 | 83.9 | n.A. |

* Analyst Forecast

HIGHLIGHTS 2019

| | |
|-----------------|---|
| NOV 2019 | Bioeq IP exclusively licenses US Marketing Rights for FYB201 to Coherus BioSciences, Inc. |
| OCT 2019 | Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar Candidate FYB202 |
| SEP 2019 | Formycon Publishes Half-Year Results for 2019 |
| JUN 2019 | Formycon Reports Further Course of Capital Measure |
| JUN 2019 | Formycon Reports Latest Status of Capital Increase |
| MAY 2019 | Formycon Reports Successful 2018 Financial Year |
| MAY 2019 | Formycon Announces News on Development Portfolio |

FINANCIAL CALENDAR

| | |
|--------------------------------------|----------------|
| Publication of Annual Report 2019 | May 2020 |
| Quarterly Statement Q1 / 2020 | June 2020 |
| Annual General Meeting 2020 | June 30, 2020 |
| Publication of Half-Year Report 2020 | September 2020 |
| Statement Nine-Month Figures 2020 | November 2020 |

MARKET DATA

| | |
|-----------------------|--|
| ISIN | DE000A1EWVY8 |
| Market Segment | Frankfurt, Stock Exchange „Scale“ |
| Market Capitalization | ~ € 300 million |
| Outstanding Shares | 10,000,000 |
| Shareholder Structure | 15 % Institutional Investors 35 % Family Offices 15 % Founders and Management 35 % Free Float |